Pluri Inc. (PLUR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pluri Inc. (PLUR) has a cash flow conversion efficiency ratio of 0.565x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.21 Million) by net assets ($-9.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pluri Inc. - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Pluri Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Pluri Inc. balance sheet liabilities for a breakdown of total debt and financial obligations.
Pluri Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pluri Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HPP Holdings Bhd
KLSE:0228
|
0.023x |
|
Investors House
HE:INVEST
|
0.029x |
|
Verena Multi Finance Tbk
JK:VRNA
|
0.085x |
|
Above Food Ingredients Inc. Common Stock
NASDAQ:ABVE
|
0.000x |
|
JAS Asset PCL
BK:J
|
0.016x |
|
Auris Minerals Ltd
AU:AUR
|
-0.016x |
|
Bellway PLC
LSE:BWY
|
0.026x |
|
CL Educate Limited
NSE:CLEDUCATE
|
0.060x |
Annual Cash Flow Conversion Efficiency for Pluri Inc. (2002–2025)
The table below shows the annual cash flow conversion efficiency of Pluri Inc. from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Pluri Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $-865.00K | $-18.21 Million | 21.053x | +732.61% |
| 2024-06-30 | $5.42 Million | $-18.02 Million | -3.328x | -122.77% |
| 2023-06-30 | $15.30 Million | $-22.86 Million | -1.494x | -31.73% |
| 2022-06-30 | $32.19 Million | $-36.50 Million | -1.134x | -109.68% |
| 2021-06-30 | $57.15 Million | $-30.91 Million | -0.541x | -15.07% |
| 2020-06-30 | $56.10 Million | $-26.37 Million | -0.470x | +65.18% |
| 2019-06-30 | $21.82 Million | $-29.45 Million | -1.350x | -79.97% |
| 2018-06-30 | $28.51 Million | $-21.38 Million | -0.750x | -4.98% |
| 2017-06-30 | $30.25 Million | $-21.61 Million | -0.714x | -47.17% |
| 2016-06-30 | $38.16 Million | $-18.52 Million | -0.485x | -36.98% |
| 2015-06-30 | $58.14 Million | $-20.61 Million | -0.354x | -15.14% |
| 2014-06-30 | $62.12 Million | $-19.12 Million | -0.308x | -4.74% |
| 2013-06-30 | $57.47 Million | $-16.89 Million | -0.294x | -238.65% |
| 2012-06-30 | $37.74 Million | $-3.27 Million | -0.087x | +34.53% |
| 2011-06-30 | $43.42 Million | $-5.75 Million | -0.133x | +90.24% |
| 2010-06-30 | $3.98 Million | $-5.41 Million | -1.358x | -8.18% |
| 2009-06-30 | $3.39 Million | $-4.26 Million | -1.256x | +35.54% |
| 2008-06-30 | $2.33 Million | $-4.54 Million | -1.948x | -274.03% |
| 2007-06-30 | $5.90 Million | $-3.07 Million | -0.521x | -116.39% |
| 2006-06-30 | $-644.23K | $-2.05 Million | 3.178x | +419.78% |
| 2005-06-30 | $1.80 Million | $-1.79 Million | -0.994x | +76.53% |
| 2004-06-30 | $357.01K | $-1.51 Million | -4.234x | -434.85% |
| 2003-06-30 | $490.42K | $-388.27K | -0.792x | -193.05% |
| 2002-06-30 | $-75.40K | $-64.16K | 0.851x | -- |
About Pluri Inc.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company's product candidates include PLX-PAD,… Read more